Statement of Translational Relevance
Early-assessment of treatment response using [ Aurora kinases are overexpressed in a variety of human tumors, including colorectal tumors, leading to dysregulation of mitosis. Over the past 20 years, aurora kinases have been extensively studied and are now recognized as promising targets for anticancer drug development (1). Aurora B kinase is the catalytic component of the chromosomal passenger complex responsible for the accurate segregation of the chromatids, histone modification, and cytokinesis (2) . The aurora kinase family comprises three related proteins that have similar homology in their catalytic domains (3) . Expression of aurora A and B is linked to the proliferation of many types of cells, whereas aurora C expression seems to be restricted to normal testicular tissue (4).
AZD1152 is a representative of a new class of small-molecule inhibitors, quinazoline-based compounds, with potent activity against specific Aurora kinases (5) (6).
AZD1152 is a quinazoline prodrug, which is rapidly converted in plasma into its active metabolite, AZD1152-hydroxyquinazoline pyrazol anilide (AZD1152-HQPA) with high affinity for aurora B and C kinases. AZD1152-HQPA is reported to have no substantial activity against a panel of other kinases (7) . In preclinical models, AZD1152 inhibited the growth of human colon, lung, and hematologic tumor xenografts (8) (9) (10). In a phase I clinical trial, AZD1152 was administered by weekly infusions to patients with advanced, pretreated solid tumors. Dose limiting toxicity (DLT) was neutropenia (grade 3), with some non hematologic toxicity. Pharmacokinetic studies confirmed rapid conversion of AZD1152 into AZD1152-HQPA. Three patients had stable disease (melanoma, nasopharyngeal carcinoma, and adenoid cystic carcinoma). Follow-up studies are ongoing, based on preclinical tumor models, which suggested that prolonged drug administration significantly increased the pro-apoptotic effect of AZD1152-HQPA. AZD1152 has been in development for the treatment of patients with breast, colon and lung cancer, and is currently being studied for the treatment of acute myeloid leukemia (11) (12) .
This study focuses on two issues: a) the assessment of AZD1152 treatment effcacy using noninvasive PET imaging, and b) the importance of considering both the de novo and salvage components of thymidine utilization in the interpretation of [ 18 F]FLT imaging studies. Two human colon carcinoma cell lines, HCT116 and SW620, and corresponding subcutaneous xenografts were studied. It was recently reported that HCT116 xenografts were highly sensitive to AZD1152 treatment (13 medium plus L-glutamine (1.5 mM), sodium bicarbonate (2.2 g/L), fetal bovine serum (10%), penicillin (100 I.U./ml) and streptomycin (100 µg/ml). SW620 human colorectal carcinoma cells were obtained from the ATCC and cultured in 72 cm 2 flasks with DMEM medium plus fetal bovine serum (10%), penicillin (100 I.U./ml) and streptomycin (100 µg/ml). Both cell lines were maintained in a humidified atmosphere (5% CO 2 /95% air) at 37°C. All cell lines were tested for mycoplasma contamination prior to experimentation using a PCR test (14) and were shown to be negative. Nine animals were treated with AZD1152 and 6 animals were maintained as controls.
Three preliminary sets of experiments with SW620 (n=9) and HCT116 (n=17) xenografts were performed, and very similar results were obtained. profile of FLT accumulation in SW620 xenografts showed no evidence of uptake followed by washout, and background radioactivity was lower at 2 hours compared to 1 hour. The image data were corrected for non-uniformity of scanner response, dead time count losses, and physical decay to the time of injection but no attenuation, scatter, or partialvolume averaging. The measured spatial resolution of the R4 is ~2.2 mm full-width half maximum (FWHM) at the center of the field of view of reconstructed images. PETmeasured tissue radioactivity was expressed as percentage of the injected dose per gram of tissue (%ID/g). Data analysis was performed on all images using ASIPro software with 2D regions of interest (ROI). ROI's were drawn around the tumor on 2D slices through the tumor and the maximum-voxel value (% injected dose/cc) was measured and used in the calculations. For the assessment of tumor radioactivity (uCi/tumor), the mean tumor radioactivity, uCi/cc, x tumor volume, cc, product was calculated) as previously described (15) . Briefly, a manual ROI was drawn around the tumor in each slice where tumor was visible. The mean accumulation (µCi/cc) and volume (cc) of each ROI was determined and summed.
Ki-67 and hematoxylin eosin immunohistochemical staining procedure. Tissue sample preparation and staining procedure to assess the effect of AZ1152-HQPA on cells proliferation was performed as previously described (16) (17).
In vitro studies. All experiments were performed in triplicate or more. concentration of AZD1152-HQPA in culture medium was 0 nM, 100 nM and 500 nM; the corresponding concentrations of DMSO were 0 mM, 0.064 mM and 0.32 mM per ml were used in the control cultures, respectively. Cell monolayers were exposed to drug containing medium for 1 or 24 hours in 6-well plates before the [ 18 F]FDG uptake experiments were performed. The AZ1152-HQPA containing medium was removed and replaced with 2 ml of DMEM high glucose medium containing [ 18 F]FDG (0.5 µCi / ml / well) containing media and a 60 minutes incubation was performed as described previously (18) . A clonogenic assay to estimate the sensitivity of cells to AZ1152-HQPA was performed as previously described (19) .
EC50 cell viability studies with methotrexate (MTX) and 5-fluorouracil (5FU) were performed to obtain a measure which reflects cell utilization of the de novo pathway of thymidine (TdR) synthesis and incorporation of endogenous TdR in DNA synthesis (20) ; the WST-1 assay was used as previously described (21) . Briefly, cells were seed on 96-well micro plates (4,000 cells/well; 8 wells/treatment dose), and incubated with MTX over a wide dose range for 72 hours. WST-1 (cell viability reagent) was added to each well and after a 4 h reaction period the optical absorbance was determined at a wavelength of 562 nm with an ELISA-reader. The optical absorbance of control (untreated) cells was taken as the 100% value; EC50 values were calculated using PRISM 5 software.
Thymidine and fluorothymidine uptake studies. Tc had decayed away. Radioactivity uptake results were expressed as a cell/medium uptake ratio: dpm/mg cell protein / dpm/µl of medium (µl medium/mg cell protein).
Cell proliferation and doubling time studies were performed as previously described (22) .
Briefly, the experimental cell lines HCT116 and SW620 were placed on 75cm plates, 100,000 viable cells per plate. 12, 24, 48, 72 and 96 hours after the placement, cells were removed by brief incubation with 0.05% Trypsin and counted. The cell number vs. time profiles were plotted and fitted to a single exponential equation to estimate doubling time.
Immunoblots using antibodies against human thymidine kinase (TK) and thymidylate
Research. or SW620 xenografts was performed at weekly intervals (Figs. 1 and 2) . The maximumvoxel FDG value (%dose/cc) and total tumor FDG radioactivity (µCi/tumor) (%dose) values were determined for each of the xenografts. The maximum-voxel FDG activity was somewhat variable in both AZD1152-treated and non-treated xenografts (Figs. 3A and 4A ).
The normalized tumor-to-adjacent tissue FDG ratio showed considerably less variation and did not change significantly over time, nor were there any significant differences between treated and non-treated animals (Figs. S1A and S1B). Measuring the total accumulation of FDG in each tumor yielded a different profile. There was a profound effect of AZD1152-treatment on total FDG accumulation in HCT116 xenografts (Fig. 3B) ; this profile change was also significant for SW620 xenografts, but it was less striking Fig. 4B ). The amount of FDG accumulated in both SW620 and HCT116 was much lower in AZD1152-treated animals than that in controls, which largely reflects differences in tumor volume (Figs 3E and 4E). After the end of the treatment, both xenografts showed a rebound effect.
The pattern of tumor radiotracer uptake with [ (Figs. 4C and 5C ), and a similar pattern was observed after calculating total FLT accumulation per tumor. Radioactivity levels in both AZD1152-treated and non-treated SW620 xenografts were at or near background levels (Fig. 4C ) and the SW620 xenograft-to-surrounding tissue ratio was very Fig S1D) . If background radioactivity is subtracted from that measured in the xenografts, the difference between HCT116 and SW620 xenografts is 37-fold (1.01±0.09 %ID/g vs 0.028±0.005 %ID/g, respectively). FLT accumulation in HCT116 xenografts was high in non-treated control animals, and was significantly less in AZD1152-treated animals (p<0.05) (Fig. 3C and 3D) . During the latter post-treatment period, FLT activity in HCT116 xenografts showed a marked rebound, reaching a significantly higher value (p<0.05) than that measured in non-treated xenografts (Fig. 3C) . The normalized tumor-to-adjacent tissue FLT ratio demonstrates a similar profile (Fig. S1 C) .
AZD1152 treatment effect on HCT116 and SW620 xenograft growth profiles.
Non-treated HCT116 and SW620 s.c. xenografts showed an exponential increase in tumor volume during the study period with estimated doubling times of 3.6 ± 0.5 and 8.1 ± 0.8 days, respectively ( Fig. 4C and 5A) . A clear response to weekly treatment with AZD1152 (100 mg/kg i.p. injections on two consecutive days per week over a 3 week interval) was observed in both HCT116 and SW620 xenografts. However, the xenograft growth profiles were different. HCT116 xenografts stopped growing immediately after the first treatment and decreased in size during the three treatment cycles. In contrast, SW620 xenografts continued to grow during AZD1152 treatment, but showed a decrease in growth rate during the three cycles of treatment. Following the cessation of treatment, there was a fairly rapid resumption of exponential growth of HCT116 xenografts with a doubling time of 5.1 ± 0.7 days. In contrast, SW620 xenografts showed a ~10 day delay in the resumption of exponential growth with a doubling time of 9.4 ± 1.5 days.
Research. 
Histology and Ki67 Immunohistochemistry
AZD1152 treatment of experimental animals, bearing HCT116 xenografts induced the formation of large multinucleated-giant tumor cells, with a marked decline in Ki67 staining over the treatment period (Fig. 5) . Samples collected from untreated animals showed normal tumor morphology with a robust pattern of Ki67 staining. In contrast, SW620 xenografts treated with AZD1152 did not demonstrate comparable changes in morphology or Ki67 expression, suggesting little or no change in proliferation (Fig 5) .
AZD1152-HQPA, MTX and 5FU treatment, in vitro.
EC50 values for AZD1152-HQPA treatment of HCT116 and SW620 cells were 10 ± 2.1 and 11 ± 3.3 nM, respectively, as determined by a clonogenic assay (Fig 6A) . However, no significant effect of AZD1152-HQPA treatment was observed on [ (Table S1 , supplement). We also tested the sensitivity of the HCT116 and SW620 cell lines to MTX and 5FU. In contrast to AZD1152-HQPA, MTX and 5FU treatment yielded markedly different sensitivity results for the two cell lines (Fig 6A) . SW620 cells were sensitive to MTX and 5FU, whereas HCT116 cells were not. To assess whether the different patterns of FLT uptake observed in HCT116 and SW620 xenografts were also reflected in cell culture uptake studies, the accumulation of [ (Fig. 6D) , and the calculated exponential growth doubling time was 14.1±0.7 and 20.9±0.4 hours, respectively. Immunoblots for thymidine kinase (TK) and thymidylate synthetase (TS) levels in HCT116 cells during rapid-exponential growth showed slightly higher expression than that in SW620 cells Fig. 6B ). Conversely, SW620 cells showed slightly higher levels of TS than HCT116 cells (Fig. 6B ). These differences are not large, but consistent with HCT 116 cells being better able to salvage thymidine in comparison to SW620 cells. However, impairment of thymidine uptake in SW620 cells cannot be excluded and needs to be investigated further. However, this finding was inconsistent with our understanding of the mechanism of AZD1152 anti-tumor effects (9) . The major regulatory pathways of glucose metabolism are largely mediated through insulin receptor (IR) signaling and the AMP activated protein kinase signaling pathways (24) (25) (26) (27) . Since the IR and the AMP signaling pathways are activated by Aurora Kinases, selective inhibition of Aurora Kinases (and Aurora Kinase B, in particular) was expected to reduce tumor glucose utilization.
When the FDG results are expressed as total tumor metabolism (or radioactivity) as has previously been suggested (15), a highly significant AZD1152 treatment effect was observed in both HCT116 and SW620 xenografts. However, the total tumor metabolic response observed in this study largely reflects differences in tumor volume between treated and non-treated tumors, not a change in glucose metabolism of tumor cells within an imaging voxel. The absence of a drug-effect on maximum-voxel FDG uptake is more clearly appreciated when the xenograft values were normalized to that of the surrounding, non-tumor tissue; this normalization accounts in part for inter-animal variations and FDG input function differences. Thus, FDG PET may not be a useful paradigm for non-invasive monitoring of AZD1152 treatment-response, at least as reflected in these two animal xenograft models. 
